Navigation Links
Study shows durable viral suppression of boosted REYATAZ in treatment-experienced HIV patients
Date:11/9/2010

(GLASGOW, 9 November 2010) Results from a European Observational Study, which included 1,294 antiretroviral (ARV)-experienced patients presented today at the Tenth International Congress on Drug Therapy in HIV Infection (HIV10), demonstrated a low rate of discontinuation and sustained virologic suppression with REYATAZ (atazanavir)/ritonavir-based regimens over a follow-up period of up to five years.1

The aim of this study was to investigate the long-term outcomes of REYATAZ/ritonavir-containing regimens in ARV-experienced patients in a real-life clinical setting. The primary endpoint of the cohort study was the proportion of patients who remained on treatment over time by baseline HIV-1 RNA level (< 500 copies/mL and >= 500 copies/mL). Secondary endpoints were reasons for discontinuation, time to virologic failure (defined as either two consecutive HIV-1 RNA >= 50 copies/mL or one HIV-1 RNA >= 50 copies/mL followed by discontinuation) and long-term safety profile.1

The results of the study revealed that 56% of patients with baseline viral suppression (< 500 copies/mL) (n= 722) and 53% of those with detectable viral load (>= 500 copies/mL) (n= 540) remained on treatment after 3 years with a median time to discontinuation of 4 versus 3.6 years, respectively. The overall discontinuation rate in the study was low (43%) with the reasons for discontinuation including adverse events (11%), withdrawn consent (6%) and lack of efficacy (6%). After three years on a REYATAZ/r-based regimen, 75% of patients with baseline HIV-1 RNA levels < 50 copies/mL remained suppressed and 51% of patients with baseline HIV-1 RNA levels >=50 copies/mL achieved and maintained virological suppression.1

Long-term safety outcomes from this real-life study were consistent with data observed in clinical trials: diarrhoea (4%), renal and urinary disorders (3%), nausea (< 1%) and jaundice (< 1%) were reported. Discontinuations due to hyperbilirubinemia were infrequent (< 1%) and no new or unexpected adverse events were observed.1

"Prior to this cohort study, less was known about long-term outcomes and the length of time on treatment in experienced patients after switching", said Professor Jan van Lunzen, M.D., Ph.D. of The University Medical Centre Hamburg-Eppendorf in Germany. "This cohort study shows in a real-life setting that a significant proportion of treatment-experienced patients stayed on an atazanavir/ritonavir-containing regimen for up to five years", he added.

Study Design

This real-life long-term cohort was a non-comparative, retrospective, observational study that collected data from three European databases (France DatAids; Germany KompNet; Sweden InfCare). Clinical data from 1,294 ARV-experienced adult patients who started an atazanavir/ritonavir-based regimen between October 2004 and March 2007 were collected every six months (maximum follow-up of five years). Patients were predominately male (74%); their median age was 43 years and 75% had prior exposure to protease inhibitors (PIs).


'/>"/>

Contact: Annie Simond
33-015-883-6566
TogoRun
Source:Eurekalert

Related medicine news :

1. Statins Dont Reduce Colon Cancer Risk, Study Finds
2. Potential drug therapy for diabetic retinopathy under study
3. Study Warns of Risks for Early Dialysis
4. Breast-Feeding Wont Rob Mom of Sleep: Study
5. Dangerous chemicals in food wrappers likely migrating to humans: U of T study
6. Brain bleeding is common with aging, UCI study finds
7. Study sheds light on aromatase inhibitor joint pain syndrome
8. APHA 2010: Study finds funding for substance abuse in Indiana lacking
9. Study: Tai Chi relieves arthritis pain, improves reach, balance, well-being
10. New Malaria Drug Proves Effective in Study of African Children
11. Psychopaths May Lack Understanding of Social Contracts: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... , ... People across the U.S. are sharpening their pencils and honing their ... in which patients and their families pay tribute to a genetic counselor by nominating ... of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Frederick area economy by obtaining investment capital for emerging technology companies. ... years that have already resulted in more than a million dollars of capital ...
(Date:6/24/2016)... ... 24, 2016 , ... Advanced Plastic Surgery Institute ( http://www.advancedplasticsurgeryinstitute.com ... its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, owns the ... Olson says the decision to support the pageant in an official capacity is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: